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Results: The maximum doses (in EQD2) for different critical 
organs in the H&N case are presented in Table 1, along with 
doses calculated without deformable registration or 
compensation for biological dose effects. For medulla, 
deformable EQD2 values are approximately 10% less than for 
the rigid raw sum; for other organs the difference varies from 
0 to 8%.  
Conclusions: Considerations of dose to organs at risk may be 
a limiting factor for treatment planning of secondary 
malignancies at the same site. This work has shown a 
complete framework to examine re-treatment planning 
accounting for different patient positions, dose sizes and 
fractionation schemes of new and previous treatments. This 
accurate summed EQD2 distribution is helpful in seeing which 
dose tolerances are reached, and where the treatment plan 
could be modified further. 
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Purpose/Objective: Hyperthermia is still regarded as the 
most potent biological sensitizer for radiotherapy and 
chemotherapy. In addition to positive results multiple phase 
III trials, in many studies a statistical significant relationships 
between applied thermal dose and treatment effectiveness 
were found. The, prospective study of Jones et al. [1] and 
the large, retrospective study of Franckena et al. [2] are 
highly convincing and demonstrate a clear rationale for 
thermal dose escalation. These findings motivated us to 
develop a software to apply HT under objective control of an 
on-line hyperthermia treatment planning (HTP) system. 
International consensus exists that the application of HT will 
benefit strongly from on-line HTP with 3D-visualization and 
control of the heating pattern in the patient. 
Materials and Methods: A software tool called VEDO 
(Visualization tool for Electromagnetic Dosimetry and 
Optimization) was created. The inputs required are: a 3D 
segmentatio of the patient model comprising all tissues, 
target, OAR and pre-calculated electromagnetic fields. VEDO 
calculates Specific Absorption Rate (SAR) distributions and 
performs optimization using a particle swarm (PS) 
optimization algorithm. Spatial optimization weighting 
regions can be manually set. Clinically important quantifiers 
like predicted target SAR dose and maximum allowed power, 
based on SAR in critical tissues, are visualized. 
Results: 
VEDO provides an instant visualization of the SAR-distribution 
(as color wash) over the patients CT using the simulated 
electric fields and real-time measured phase and amplitude 
of the signals fed to each antenna element. Pre-treatment, 
VEDO is used by the MDs for decision making. During 
treatment, VEDO helps the operator to correlate the location 
of pain-complaints to predicted high SAR values near the 
indicated region; allowing re-optimization for reduction of 
the SAR at the indicated 'hot-spot' area. With this, complaint-
adaptive SAR steering is used to convert hotspots in re-
optimized settings, with reduced local SAR, that can directly 
be applied to the patient anatomy. In patients with head and 
neck tumors complaint adaptive SAR steering resulted in at 
least 20% increase of the SAR delivered to the target.  
Conclusions: VEDO is completely objective and quantitative, 
and can be evaluated on its effectiveness. The latter is an 
important step towards abandoning treatment optimization 
based on experience of the hyperthermia staff members. The 
simulations using the patient anatomy also provides much 
more insight as compared to experimental SAR measurements 
in homogeneous phantoms. Clinical application of VEDO 
shows that the workflow is feasible and that re-optimization 
based on patient discomfort is effective in reducing 
complaints.  
1 - Jones EL et al. Randomized trial of hyperthermia and 
radiation for superficial tumors. JCO. 2005, 3079-85. 
2 - Franckena M et al. Hyperthermia dose-effect relationship 
in 420 patients with cervical cancer treated with combined 
radiotherapy and hyperthermia. EJC. 2009, 1969-78.  
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Purpose/Objective: To determine the relationship between 
recurrence locations and pre-RT 18F-FDG PET SUV data for 
patients diagnosed with HNSCC. 
Materials and Methods: Based on a patient group of 90 
patients treated with IMRT or VMAT, a retrospective 
investigation of local variations in TCP depending on 
pretreatment 18F-FDG PET SUV through use of recurrence 
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locations was made. The inclusion criteria were patients 
diagnosed with HNSCC, completion of radiotherapy, 18F-FDG 
PET/CT based treatment planning and at least 6 months 
follow up time after completion of RT. The recurrence free 
frequency for this population was 77%.  
The patients went through RT with CTV volumes delineated 
for the lymph node regions and the primary tumor 
respectively and with the dosage of 70 Gy EQD2. 
The recurrence volumes were delineated on the treatment 
planning CT images by an experienced radiation oncologist 
guided by post treatment follow up data, post-PET-imaging 
and post-CT-imaging, but without use of the pretreatment 
PET images used in treatment planning.  
For the subpopulation with recurrences, the distribution of 
SUV in the recurrence volumes was analyzed patient by 
patient. CTV volumes without any recurrence were excluded. 
For each patient, a volume CTVcontrol was defined as the CTV 
volume excluding the recurrence volume, CTVrecurrence. Voxels 
with SUV lower than 1 were excluded and the remaining SUV 
were normalized through dividing by SUVmax. Probability Of 
Failure (POF) was defined as the SUV frequency in CTVrecurrence 
divided by the SUV frequency in the union of CTVrecurrence and 
CTVcontrol. The voxel specific TCP for 70 Gy EQD2 for each 
normalized SUV was defined as unity subtracted by the 
product of the recurrence frequency, 23%, with POF. 
Results: POF was found to approach unity when SUV goes to 
SUVmax, hence the correlation of location of recurrence with 
increasing SUV was strong. Figure 1 displays how these 
finding translates into a voxel specific TCP at the given dose 
70 Gy EQD2. 
 
 
Figure 1: Voxel specific TCP at 70 Gy EQD2 for each patient, 
represented as lines in different colors. 
The dashed line represents the voxel specific TCP at 70 Gy 
EQD2 merged for all patients.  
Conclusions: This study presents a feasible method for 
determining relationships between tumor control and image 
information in voxels based on retrospective data for patient 
groups demonstrating localized recurrences. The obtained 
results could form the basis for prescribing dose at a voxel 
level, i.e. for dose painting by numbers. 
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Purpose/Objective: Dose escalation to the gross tumour 
volume (GTV) has been proposed to improve local control in 
oesophageal cancer. However, a recent planning study for 
mid-oesophageal tumours [Warren IJROBP 2014] found that a 
simultaneous integrated boost (SIB) with acceptable heart 
and lung sparing was not possible for ~25% of patients when 
using arctherapy (RA). Intensity modulated proton therapy 
(IMPT) has been proposed to improve target coverage and 
normal tissue sparing compared to photon treatments [Welsh 
IJROBP 2011]. In this work optimal SIB RA and IMPT treatment 
plans and their robustness to set-up error and proton range 
error are compared.  
Materials and Methods: 21 mid-oesophageal cancer patients 
representative of planning target volume (PTV) size were 
selected from the SCOPE1 (ISRCTN 47718479) database (mean 
PTV = 334 cm3). These patients had mean PTV 327 cm3, range 
140-591 cm3. The protocol standard margins were re-applied 
to trial-derived GTV without modification to generate PTV1. 
A boost volume (PTV2) was created by adding an isotropic 0.5 
cm margin to the GTV. The dose prescription (25 fractions) 
was 50 Gy to PTV1 and 62.5 Gy to PTV2. Two optimal 
treatment plans were then created for each patient using 
Eclipse v13 (Varian): a RA plan (2 arcs, 6MV) and an IMPT plan 
(70 – 250 MeV) using the beam arrangement described by 
Welsh. Dose-volume metrics for PTV1, PTV2, GTV, heart, and 
lung were compared for each patient for the optimal IMPT 
and RA plans (Wilcoxon test). Robustness was evaluated using 
the Plan Uncertainty tool provided in Eclipse. Set-up errors of 
±0.5cm radially and ± 0.7cm axially were simulated to 
generate 6 RA uncertainty plans. An additional range error of 
±3.5% was included for protons, to generate 12 proton 
uncertainty dose distributions. The median values of RA and 
IMPT uncertainty plans were compared using the Mann 
Whitney test.  
Results: Optimal IMPT plans were able to achieve all dose 
constraints for 20/21 patients: the heart mean dose limit of 
25 Gy was exceeded for one patient (25.3 Gy), where there is 
significant overlap with the PTV. IMPT reduced mean lung 
dose for each patient by 49.3% (median, IQR: 46.3 – 52.4%, 
Z=-4.02, p<.001). Mean heart dose was reduced by 40.3% 
(median, IQR: 37.8 – 45.3%, Z=-4.02, p<.001). Analysis of RA 
and IMPT uncertainty plans showed that differences in 
PTV1V95% coverage were not statistically significant for 19/21 
patients. Boost volume coverage (PTV2 V95) was less robust 
for IMPT, and plan uncertainty produced median GTV D98 
across all patients RA= 62.9 Gy (IQR: 62.8 – 63.0 Gy) and 
IMPT= 62.1 Gy (IQR: 61.8 – 62.4 Gy) (p values <.001 to .03). 
Conclusions: IMPT plans have potential for significantly 
sparing lung and heart for all mid-oesophageal patients 
compared to RA. However, the SIB proton plans appear less 
robust for coverage of the dose boost region than photon 
plans, which may compromise the predicted improvement in 
local tumour control for these patients. 
